Boston, USA & Brisbane, Australia – September 8 – 2026 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that management will participate in the following upcoming investor and industry conferences:
Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 16, 2026
Time: 10:00 AM – 10:35 AM ET
Presenter: Philina Lee, Ph.D., Chief Executive Officer
Format: Company Presentation
Oppenheimer 4th Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Date: September 17, 2026
Time: 11:50 AM – 1:20 PM ET
Presenter: Philina Lee, Ph.D., Chief Executive Officer
Format: Company Presentation
Time: 1:35 PM – 2:20 PM ET
Presenter: Anna Karmann, MD Ph.D., Chief Medical Officer
Panel title: Putting TRT Clinical Data in Context
Fierce Pharma Manufacturing Day
Date: September 29, 2026
Time: 10:05 AM – 10:35 AM ET
Presenter: Justyna Kelly, Chief Technology Officer
Panel Title: Bio/Pharma Manufacturing in 2027 and Beyond: Top of the Innovator Manufacturing Agenda
About AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company developing next-generation targeted alpha therapies for cancer. Through its vertically integrated platform spanning proprietary Lead-212 technology, secure isotope supply, advanced manufacturing and clinical development, the Company is unlocking the full potential of targeted alpha therapy. With integrated operations across North America and Australia, AdvanCell is advancing a pipeline of differentiated precision radiopharmaceuticals designed to improve outcomes for patients with cancer worldwide. For more information, visit www.advancell.com.au and follow us on LinkedIn.
Company Contact
contact@advancell.com.au
Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
